We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Thermo Fisher Scientific - Direct Effect Media

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Rapid Ovarian Cancer Test Cuts Surgical Procedure Time and Infection Risk

By HospiMedica International staff writers
Posted on 12 May 2022
Print article
Image: OvaCis rapid test is slated to launch in EU and Southeast Asia by 2022 end (Photo courtesy of INEX Innovate)
Image: OvaCis rapid test is slated to launch in EU and Southeast Asia by 2022 end (Photo courtesy of INEX Innovate)

The current standard of practice for ovarian cancer screening, called frozen section, increases the surgical procedure time by up to 60 minutes, consequently increasing the risk of infections and anesthesia. Frozen section is also dependent on the skill of the pathologist conducting the biopsy sections, thus ovarian cancers (especially early ovarian cancers) can be missed. Now, a first of its kind point-of-care (POCT) test discriminates benign from malignant ovarian cysts in an operating theater setting and significantly reduces surgical procedure time by providing results in 15 minutes.

The OvaCis Rapid Test from INEX Innovate (Singapore) works by identifying a protein biomarker (haptoglobin) evenly distributed in ovarian cysts fluid to determine if the cysts are benign or malignant. The reagents in the device combine to yield a colorimetric reaction which displays if the cancer is malignant (positive) or benign (negative). The test was developed as a rapid test format, and has proved to be user friendly requiring only minimal training and five minutes of hands-on time.

OvaCis’ reliance on cyst fluid which is homogenous results in higher accuracy. OvaCis is ideal for medical settings with no on-site facilities for histology, and costs less than frozen section. It does not require trained pathologists, substantially reduces operating theatre time, and frees up resources in the laboratory. OvaCis Rapid Test has obtained a CE mark and is slated to launch in the EU and Southeast Asian markets by the end of 2022. A previous iteration of OvaCis was launched in 2019, and the latest improvements now mean an extension of the product's shelf life to a minimum of 18 months at room temperature storage. This makes it convenient to store the kits in a primary healthcare setting.

“Ovarian cysts are a very common women's health condition. In fact, as many as 18% of women have them at some point in their lives and about 8% of premenopausal women develop large cysts that need treatment,” said Kane Black, Chief Executive of INEX Innovate. “With limited diagnostic options, this is an underserved population. This is mainly because the industry has been largely focused on upstream screening procedures such as early cancer detection.”

“OvaCis empowers surgeons to make fast informed evidence-based decisions within the confines of a high pressure surgical environment. By providing results in 15 minutes, the surgical procedure time is significantly reduced, thus greatly reducing the risk of infection. It also adds a layer of assurance for clinicians to make decisions about the extent of the surgery and the final reproductive status of a patient,” added Black.

Related Links:
INEX Innovate 


Print article

Channels

Critical Care

view channel
Image: Triage Cardiac Panel is a rapid, POC fluorescence immunoassay used with Triage MeterPro (Photo courtesy of Quidel)

Quidel Triage Cardiac Panel Facilitates Rapid POC Diagnosis of Chest Pain Patients in ED

Chest and abdominal pain are the most common reasons that persons aged 15 years and over visit the emergency department (ED). Because both emergency and non-emergency care are provided, symptoms vary widely... Read more

Surgical Techniques

view channel
Image: A minimally invasive diagnostic biomarker strategy has proven successful in detecting early esophageal cancer (Photo courtesy of Pexels)

Minimally Invasive Device Combined With Molecular Biomarkers Detects Early Esophageal Cancer

Esophageal cancer remains the sixth-most common cause of cancer death worldwide, claiming the lives of more than half a million people annually. Esophageal squamous cell carcinoma (ESCC) comprises 80%... Read more

Patient Care

view channel
Image: Future wearable health tech could measure gases released from skin (Photo courtesy of Pexels)

Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases

Most research on measuring human biomarkers, which are measures of a body’s health, rely on electrical signals to sense the chemicals excreted in sweat. But sensors that rely on perspiration often require... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.